CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations
Pooled data from two CANVAS trials suggest that cardioprotection is likely a class effect with SGLT2 inhibitors, but it comes at the price of toe amputations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
J & J diabetes drug shows heart benefit in large safety study
(Reuters) - Johnson& Johnson's type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting on Monday. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
J & J Drug Prevents Heart Attacks At Cost Of Amputated Toes
In a blow to J&J, for every three heart attacks, strokes, or cardiovascular deaths prevented by Invokana, there were two amputations, 71% of them of toes or the lower foot, according to the results of the 10,142-patient study. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 12, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:JNJ NYSE:MRK NYSE:LLY Source Type: news
7 medtech stories we missed this week: May 26, 2017
[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning.
1. Merck inks exclusive licensing agreement for Alzheimer’s antibody
Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufa...
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Patient Monitoring Pharma Pharmaceuticals Research & Development Surgical EarlySense Janssen Pharmaceuticals Life Spine Inc. Masimo MedTech Merck Midmark Procept BioRobotics Shenzhen Lachesis Mhealth Teijin Pharma Thermi Source Type: news
FDA Warns of Amputation Risk Linked to Newer Diabetes Drug
The FDA has called for a new boxed warning to be added to canagliflozin product labels based on a heightened risk for leg and foot amputations associated with use of the drug. (Source: AAFP News)
Source: AAFP News - May 22, 2017 Category: Primary Care Source Type: news
FDA Warning: Diabetes Drug Has Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says (Source: WebMD Health)
Source: WebMD Health - May 17, 2017 Category: Consumer Health News Source Type: news
Diabetes Drug Gets FDA Warning Due to Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says (Source: WebMD Health)
Source: WebMD Health - May 17, 2017 Category: Consumer Health News Source Type: news
Diabetes Drug Gets FDA Warning Due to Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Diabetes Type 2, Limb Loss (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 17, 2017 Category: Consumer Health News Source Type: news
Diabetes Drug Gets FDA Warning Due to Amputation Risk
WEDNESDAY, May 17, 2017 -- The type 2 diabetes prescription drug canagliflozin (brand names Invokana, Invokamet, Invokamet XR) appears to increase the risk of leg and foot amputations, the U.S. Food and Drug Administration now says.
The FDA is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 17, 2017 Category: General Medicine Source Type: news
FDA Adds Boxed Warning to Canagliflozin for Increased Amputation Risk (FREE)
By Kristin J. Kelley
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The FDA is adding new warnings — including a boxed warning — to labels for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 17, 2017 Category: Primary Care Source Type: news
FDA warns of foot, leg amputations with J & J diabetes drug
(Reuters) - Johnson& Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA: Boxed Warning for Canagliflozin on Amputation Risk
(MedPage Today) -- Post-marketing trial data show doubled rates compared to placebo (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 16, 2017 Category: Endocrinology Source Type: news
FDA Adding Boxed Warning to Canagliflozin for Amputation Risk FDA Adding Boxed Warning to Canagliflozin for Amputation Risk
On the basis of new information from two cardiovascular outcomes trials suggesting a doubled amputation risk, the FDA will now require a boxed warning on canagliflozin ' s label.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Adds Boxed Warning to Canagliflozin for Amputation Risk FDA Adds Boxed Warning to Canagliflozin for Amputation Risk
On the basis of new information from two cardiovascular outcomes trials suggesting a doubled amputation risk, the FDA will now require a boxed warning on canagliflozin ' s label.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2017 Category: Drugs & Pharmacology Source Type: news
